Decoy Therapeutics Q3 10-Q: Going Concern, $8.2M Cash, New Nasdaq Delisting Risk
DCOY sits 17% above its 52-week low of $0.9.
Summary
Decoy Therapeutics reported a $7.59 million nine-month net loss, $8.17 million of cash (about $2.5 million restricted), a going-concern warning, and a new risk that a proposed Nasdaq $5 million market value rule could delist the stock with no cure period.
Key Events · Earnings and Guidance · DCOY
-
Q3 Net Loss Widens to $7.59M
Nine-month net loss was $7,586,258 versus $3,540,825 a year earlier, driven by R&D of $3.63 million and G&A of $4.61 million after the November 2025 merger.
-
Cash Falls to $8.17M, Runway Into Early 2027
Cash, cash equivalents and restricted cash were $8,168,071 at September 30, 2026, down from $10,709,937 at December 31, 2025; about $2.5 million is restricted under the Gates Foundation grant.
-
Going Concern Doubt Reiterated
Management states substantial doubt exists about the company's ability to continue as a going concern and that existing cash will not fund operations through one year from the financial statements' issuance date.
-
New Nasdaq MVLS Delisting Risk
A new risk factor flags Nasdaq's proposed $5.0 million market value of listed securities rule, stayed pending SEC review, which could delist the stock with no compliance or cure period; the company says its market value is already below that threshold.
Analysis · DCOY · Life Sciences
The cash problem is now explicit for this pre-clinical biotech, which has no product revenue: $8.17 million of cash and restricted cash at September 30, of which roughly $2.5 million is locked up under the Gates Foundation grant, against a $7.59 million nine-month operating loss. Management says existing cash funds operations only into early 2027 and repeats substantial doubt about the going concern. What's new is a risk factor on Nasdaq's proposed $5.0 million market value of listed securities rule — currently stayed pending SEC review — which, if approved, could delist the stock with no cure period; the company notes its market value already sits below that threshold. With 5.29 million warrants outstanding at a $7.27 weighted-average strike, far above the current share price, the equity is deeply out of the money and further raises will be needed.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCOY was trading at $1.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.90 to $20.76. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.